Amethyst Healthcare expands cancer care footprint in Portugal

Amethyst Healthcare, the Netherlands-based cancer care provider, has entered the Portuguese market with the acquisition of private radiotherapy group Júlio Teixeira. The move marks another step in Amethyst’s pan-European expansion strategy and broadens its clinical reach by around 3,000 additional patients per year.

Júlio Teixeira, founded in Porto in 1994, operates from two key sites — Instituto CUF, northern Portugal’s main private healthcare hub, and the radiotherapy department of Braga Hospital. These locations strengthen Amethyst’s position within Portugal’s private healthcare ecosystem while offering opportunities for regional service integration and patient flow optimisation.

The acquisition follows Amethyst’s change of ownership earlier this year, when Fremman Capital acquired the group from TRG. Amethyst now runs 21 centres across seven countries, including France, Italy, and the UK, employing around 500 full-time staff and 100 doctors. Its treatment model blends local clinical autonomy with centralised management to deliver standardised quality care and operational efficiency.

Radiotherapy remains Amethyst’s core revenue driver, accounting for roughly 75% of turnover, with chemotherapy and diagnostic imaging completing its oncology offering. The company’s entry into Portugal aligns with plans to expand in key southern European markets, with further acquisitions under consideration in Lisbon and the country’s southern regions.

Amethyst’s acquisition of Júlio Teixeira underscores growing investor confidence in private oncology care models built on scalable infrastructure and collaborative public-private frameworks.

Explore the full report for deeper insights into Amethyst’s European growth strategy and its plans for Portugal’s private oncology sector.